CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...